All In Biotech

Drug Trial Radar · NCT05271292

Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.

A Phase 1b/2, Single-Arm, Open-Label, Dose-Escalation, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Chiauranib for the Treatment of Advanced Solid Tumors and Relapsed/Refractory SCLC

Last checked: Nov 19, 2026Latest source record: Jul 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

36

Planned (sponsor's estimate)

Start

Aug 26, 2022

Primary completion

Mar 2025

Study completion May 2025

Sponsor

Lead sponsor
Chipscreen Biosciences, Ltd.Industry
Sponsor type
Industry
First posted
Mar 9, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1b/2, single-arm, open-label, dose-escalation study including 2 stages: Phase 1b: Dose-Escalation Stage (Single-Dose and Consecutive-Dose Periods) Phase 2: recommended Phase 2 dose (RP2D) of chiauranib will be given to all patients enrolled in this phase once daily for 28-day cycles continuously with no interruption between cycles.

Conditions

  • Small Cell Lung Cancer
  • Advanced Solid Malignant Tumor

Interventions

  • ChiauranibDrug

    Phase 1b: Each patient will undergo both a single-dose period (6 days) and a consecutive-dose (1 cycle of 28 days) period Phase 2: Patients will take the RP2D once daily for 28-day cycles continuously with no interruption between cycles

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse events (AEs) and other safety parametersTime frame: Until 30 days after a patient takes the last dose of the study drug
  2. Incidence and characteristics of DLTsTime frame: 34 days
  3. MTD and recommended Phase 2 dose (RP2D)Time frame: 34 days

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • California Cancer Associates-Encintas

    Encinitas, California · Recruiting

  • Providence/St. Joe Cancer Institute/Crosson Cancer Institute

    Fullerton, California · Recruiting

  • Winship Cancer Institute of Emory University

    Atlanta, Georgia · Recruiting

  • Dana Farber Cancer Institue

    Boston, Massachusetts · Recruiting

  • Karmanos Cancer Institute

    Detroit, Michigan · Recruiting

  • Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevada · Recruiting

  • Gabrail Cancer Center Research

    Canton, Ohio · Recruiting

  • OU Health

    Oklahoma City, Oklahoma · Recruiting

  • Sarah Cannon Research Center

    Nashville, Tennessee · Recruiting

  • North Houston Cancer Clinics

    Huntsville, Texas · Recruiting

  • Virginia Cancer Specialists

    Fairfax, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.